Growing Demand for Surgical Hair Transplant to Drive the Alopecia Treatment Market

A sedentary lifestyle, unhealthy eating habits, and growing stress levels are increasingly responsible for severe hair loss and damage, also known as alopecia. Ageing, hormonal imbalance, and increasing prevalence of cancer, arthritis, hypertension, and depression are other factors causing alopecia. Thus, the alopecia treatment market is anticipated to witness significant growth in the coming years owing to a surge in the prevalence of alopecia. The number of people seeking alopecia treatment is extremely high in developed nations. However, increased healthcare expenditure has spurred the demand for alopecia treatment in developing nations such as China and India as well.

Browse through Alopecia Treatment Market report to know what factors will shape the market by 2024: http://www.transparencymarketresearch.com/alopecia-market.html

The alopecia treatment market is segmented on the basis of product, gender, end user, and geography. By product, the market is segmented into shampoos and conditioners, vitamins and supplements, and other (gels, oils, and serums). On the basis of end user, the market is segmented into homecare settings, dermatology clinics, and others.

The report covers an exhaustive analysis on the alopecia treatment market segments, including the leading, declining, and fastest growing segments. It comprises the analysis of market dynamics, the market size and forecast, and the trends, threats, and opportunities. The study also comprises the vendor landscape, degree of competition, threat of new entrants, and the bargaining power of buyers and suppliers.

Overview of the Alopecia Treatment Market

According to the American Hair Loss Association, 95% of the hair loss in men is caused by androgenetic alopecia. The Association also states Moreover, the body also states that around 800 thousand people are undergoing some form of treatment for hair loss across the globe. The rise in the geriatric population and increasing hypertension and depression among the middle aged population are some of the factors driving the alopecia treatment market. A growing demand for surgical hair transplant is expected to drive the global alopecia treatment market in the coming years. An increase in the disposable income of the people, technological advancements in hair treatment medical devices, and a growing emphasis on looking good are some of the other factors driving the market. Moreover, the easy accessibility to scalp treatment is also helping the market to grow.

The global alopecia treatment market is expected to be restricted by the high cost of medications. The probable side effects, reactions, and allergies caused by alopecia treatments will further hamper the growth of the market. Decreased libido, high BP, increase in the heart rate, and erectile dysfunction are some of the side effects caused by alopecia treatment, threatening the market’s growth. However, technological advancements and the development of novel therapeutic drugs are expected to bring new opportunities for growth in the market.

On the basis of geography, the global alopecia treatment market is segmented into Europe, Asia Pacific, North America, and the Rest of the World, of which North America is currently the largest segment. North America is also the most significant revenue generator at present, owing to the rise in hair loss among people and the high treatment rates. The high disposable income of the people and the availability of innovative therapeutic solutions are also factors driving the growth of the market in North America.

Get accurate market forecast and analysis on the Alopecia Treatment Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=11915

Companies Mentioned in the Report

The report profiles leading players in the global alopecia treatment market. Important information pertaining to players, such as their recent developments, product picture, specifications, and price, and the challenges faced by them are included. Additionally, the report covers strategies adopted by key players to grow in the alopecia treatment market. The key vendors include Vitabiotics, Sun Pharma, Merck & Co., Alpecin, Dr. Reddy’s Laboratories, Cipla, Johnson & Johnson, Kirkland Signature, Phyto Ales Group, and Lifes2good.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Colorectal Cancer Treatment Market: Future Demand and Growth Analysis 2024

Colorectal cancer is cancer that starts in the colon or rectum. The colon and the rectum are parts of the large intestine, which is the lower part of the body’s digestive system. The colon absorbs water and nutrients from the food and stores waste matter (stool). Stool moves from the colon into the rectum before it leaves the body. Colorectal cancer often begins as a growth called a polyp, which may form on the inner wall of the colon or rectum. Some polyps become cancer over time. Finding and removing polyps can prevent colorectal cancer. During digestion, food moves through the stomach and small intestine into the colon. Most colorectal cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Some of the commonly seen symptoms of colorectal cancer are blood in the weight loss, fatigue, stool, and irregular bowel movements. Colorectal cancer is a result of uncontrolled cell growth that occurs in the appendix, colon, and the rectum region.

Browse through Colorectal Cancer Treatment Market report to know what factors will shape the market by 2024: http://www.transparencymarketresearch.com/colorectal-cancer-treatment-market.html

According to American Cancer Society, in United States when men and women are considered individually colorectal cancer is the third prominent cause of cancer-related mortality, and the second prominent cause when both sexes are combined. With the use of fecal occult blood tests and colonoscopies, which check for blood in the stool the deaths from colorectal cancer have decreased. Ageing, fatty diet, excessive consumption of red meat or alcohol, male gender, obesity, smoking are the most commonly observed causes for colorectal cancer.  Most colorectal cancers originate as a polyp, a growth in the tissue that lines the internal surface of the rectum or colon and it is common in people older than 50 years of age, and most are not cancer.

The global market for colorectal cancer market is segmented on basis of treatment options, Colorectal Cancer Stage, end user and geography:

Segmentation by Diagnosis

> Fecal Occult Blood Tests
> Stool DNA test
> Sigmoidoscopy
> Colonoscopy
> Virtual Colonoscopy
> Double-contrast Barium Enema
> Others

Segmentation by Treatment Options

> Surgery
> Radiation therapy
> Chemotherapy
> Targeted therapy
> Others

Segmentation by Colorectal Cancer Stage

> Stage 0
> Stage I
> Stage II
> Stage III
> Stage IV (Metastatic)

Increasing adoption of western diet which are high in fat and low in fiber is expected to boost the growth of colorectal cancer market over the forecast period. Based on diagnosis, colorectal cancer are classified as fecal occult blood tests, stool DNA test, sigmoidoscopy, colonoscopy, virtual colonoscopy, double-contrast barium enema, others.

Based on treatment option, colorectal cancer are classified as surgery, radiation therapy, chemotherapy and targeted therapy. Surgery remains the most effective treatment for colorectal cancer. Radiation therapy reduces the chance of cancer spread or recurrence and is effective as additional or adjuvant therapy either before or after surgery. The segment is expected to grow rapidly over the forecast period due to increasing technological advancement and increasing awareness.

Based on colorectal cancer stage, colorectal cancer has been segmented into stage 0, stage I, stage II, stage III, and stage IV (metastatic). According to National Cancer Institute, in 2016, an estimated 134,490 people in the United States will be diagnosed with colorectal cancer and 49,190 people will die from it. In general, stages 0, I, II, and III are often curable with surgery. Patients with stage II and III rectal cancer receives radiation therapy with chemotherapy either before or after surgery. Patients with stage III colorectal cancer, and some with stage II, receive chemotherapy after surgery to increase the chance of eliminating the disease. Stage IV is not often curable, but it effects can be reduced, and the growth of the cancer and the symptoms of the disease can be managed.

On the basis of regional presence, global colorectal cancer market is segmented into five key regions viz.  North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to lead the global colorectal cancer market for due to aging population. Due to increase in screening of colorectal cancer and changes in some risk factors such as a decline in smoking and consumption of alcohol is decreasing the rate of new colorectal cancer cases and deaths among adults aged 50 years and above.

Get accurate market forecast and analysis on the Colorectal Cancer Treatment Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=15344

Some of the major players in global colorectal cancer market are Hoffmann La Roche, Debiopharm Group, Merck KGaA, Vaccinogen BD, AEterna Zentaris, and  Keryx Biopharmaceuticals, Inc., etc.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

North America Wheelchair Accessible Vehicle Converters Market to Reach US$3.47 Bn by 2024

The North America market for wheelchair accessible vehicle converters demonstrates a fragmented competitive landscape, states a new research study by Transparency Market Research (TMR). The top three players in this market, namely, Vantage Mobility International, BraunAbility, and Mobility Ventures LLC., held more than 65% of the overall market in 2015.

This 186 page report gives readers a comprehensive overview of the North America Wheelchair Accessible Vehicle Converters Market. Browse through 38 data tables and 78 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/north-america-wheelchair-accessible-vehicle-converters-market.html

These players are mostly relying on introducing advanced products in the market for the expansion of their businesses. A shift in their focus towards mergers and acquisitions, in a bid to strengthen their presence, can be observed in the near future, reports the research study.

According to the research report, the market for wheelchair accessible vehicle converters in North America presented an opportunity worth US$1.74 bn in 2015. Rising at a CAGR of 5.30% during the period from 2016 to 2024, the market is expected to display a substantial growth in its size with the valuation reaching US$3.47 bn by the end of 2024. Full size vehicles have emerged as the leading contributors to this market due to their high prices. Medium size vehicles, however, are expected to lead in terms of sales volume over the next few years.

Side Entry Segment to Experience Strong Rise

The research report has analyzed the North America market for wheelchair accessible vehicle converters on the basis of a number of parameters. On the basis of entry mode, the report classifies this market into side entry and rear entry. Side entry wheelchair accessible vehicles converters has been reporting a much higher demand than the rear entry ones. Researchers anticipate the trend to remain so over the forecast period, thanks to the ability of side entry wheelchair accessible vehicles to enable the patient to drive from a wheelchair or sit in the front passenger position or the driver’s position in a wheelchair. The availability of enter and exit curbside and more storage space is also projected to boost the demand for side entry wheelchair accessible vehicles in the years to come, supporting this segment.

Geographically, the market study has segmented the North America wheelchair accessible vehicle converters market into the U.S. and Canada. The U.S. dominated the overall market in 2015 with a share of nearly 95% and is predicted to continue on the top throughout the period of the forecast. The presence of a massive disabled population base, an upswing in the cases of trauma resulting in disability, and the increasing uptake of wheelchair accessible vehicles, boosted by the government funding and the rising number of awareness initiatives by vehicle converter manufacturers, are also expected to propel the U.S. market for wheelchair accessible vehicle converters in the near future.

Increasing Number of Patients Suffering from Disability of Mobility to Fuel Demand

“The increasing number of patients with disability has influenced the North America market for wheelchair accessible vehicle converters to a great extent,” states the author of this report. In 2015, the number of people using wheelchairs in the U.S. was nearly 3.3 million, which is likely to rise tremendously in the near future on account of the increasing prevalence of disability of mobility among people due to the escalating cases of trauma, accidental injuries, sports injuries, and the surge in the geriatric population. This, as a result, is likely to fuel the demand for wheelchair accessible vehicle converters further over the forecast period.

Get accurate market forecast and analysis on the North America Wheelchair Accessible Vehicle Converters Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16094

The rising demand for user-friendly accessible vehicles is also expected to boost this market in the near future. However, the high price of these vehicle may restrict the growth of this market over the next few years, states the research report.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Technological Advancements to Impel Surgical Drainage Devices Market Growth

Global Surgical Drainage Device Market: Overview

Surgical drainage devices are tubes used to remove excess liquid and air. The fluid to be drained may include, blood, serum, pus, urine, bile or lymph. Surgical drains are used in a wide variety of different types of surgery such as orthopedics surgery, cardiovascular surgery, neurosurgery, plastic surgery etc. Common use of surgical drainage device is prophylactic post-surgery to prevent accumulation of fluid e.g. blood or pus. Surgical drains are available in various sizes and configurations and are economical. Surgical drains are used for shorter or longer periods based on severity of wound or disease. The report consists of an executive summary that provides information about the products, its segments along with a market snapshot and comparative analysis by geography, in terms of revenue %, for 2015.

This 164 page report gives readers a comprehensive overview of the Surgical Drainage Devices Market. Browse through 24 data tables and 65 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/surgical-drainage-devices-market.html

A detailed overview of market dynamics, including the drivers, restraints, and opportunities of the surgical drainage devices market, along with porter’s analysis, value chain analysis, of the global market, has been provided in this report. Market revenue analysis for all the above mentioned segments has been provided for the forecast period of 2016-2024, considering 2015 as the base year, and 2014 as the historical year, along with compound annual growth rate (CAGR %), for the forecast period of 2016-2024. Market share estimations were based on in-depth analysis and study of products, and their features etc.

Global Surgical Drainage Device Market: Scope of the Study

This report provides in-depth analysis of the surgical drainage devices market. The stakeholders for this report include companies involved in the manufacturing of surgical drainage devices. Executive summary section is included snapshot on stakeholders in this report, which summarizes the market size, trends and competition in different regions. Market players and Market share analysis is analyzed to signify percentage share of the major players operating in the market. Furthermore, the report includes market attractiveness analysis by geography that depicts the most attractive and significant region in the global market in 2015.

The research methodology is a combination of primary and secondary research. Primary research includes information collected via e-mails, and telephonic interviews of key opinion leaders (KOL), and forms the bulk of our research. Secondary research includes information collected from various sources, by study of company websites, annual reports, stock analysis presentations, press releases, and various national and international databases.

Global Surgical Drainage Device Market: Segmentation

Based on product type, the global market has been segmented into active drainage and passive drainage. Active drainage segment is growing at a CAGR of 2.8% from 2016 to 2014 due to it several advantages and application. Based on application, the surgical drainage devices are segmented into General Surgery, Orthopedics, Thoracic and Cardiovascular, Obstetrics/Gynecology, Plastic/Reconstructive Surgery, Neurosurgery. The orthopedics segment is expected to grow at a highest CAGR between 2016 and 2024. Based on end users, the market is segmented as hospitals, specialty clinics, and ambulatory surgery centers.

Based on geography, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The regions are further segmented into major countries which include, U.S., Canada, Germany, U.K., France, Italy, Spain, Rest of Europe, China, Japan, India, Australia, Rest of Asia Pacific, Brazil, Mexico, Rest of Latin America, Saudi Arabia, South Africa, and Rest of Middle East & Africa.

Get accurate market forecast and analysis on the Surgical Drainage Devices Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=21800

Companies Mentioned in this Report

The report also comprises list of major players in the market, their SWOT analysis, market share of these players in the Surgical drainage devices Diagnostic market, key business strategies, product portfolios, and recent developments. Key market players profiled in this report include, B. Braun Melsungen AG, C. R. Bard, Inc., Medtronic plc, Teleflex Incorporated, Stryker Corporation, Johnson & Johnson, Cardinal Health, REDAX S.P.A., Smith & Nephew plc, Acelity L.P. Inc., Integra LifeSciences Corporation, and Cook Medical among others.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Medical Image Analysis Software Market is Anticipated to Expand at an 8.10% CAGR by 2024

Global Medical Image Analysis Software Market: Snapshot

With the rising prevalence of chronic diseases, such as cancer and various other cardiovascular disorders, the global market for medical image analysis software has witnessed a substantial rise in its size and scope. Analysts foresee an upward growth is this market over the next few years, thanks to the advent of 4D imaging technique and the swelling demand for medical imaging. The market, which presented an opportunity worth US$2.35 bn in 2015, is anticipated to expand at an 8.10% CAGR between 2016 and 2024 and touch a value of US$4.66 bn by the end of 2024.

This 223 page report gives readers a comprehensive overview of the Medical Image Analysis Software Market. Browse through 36 data tables and 108 figures to unlock the hidden opportunities in this market: http://www.transparencymarketresearch.com/medical-image-analysis-software-market.html

Integrated Software to Enjoy Higher Demand than Standalone Software

Integrated software and standalone software are the two main types of medical image analysis software available across the world. Among the two, the integrated software segment, which has been leading this market since the last few years, is projected to dominate it as well over the forthcoming years, thanks to the rising awareness about the advantages of integrated software systems, such as interlinking of the database and storing of the images for further analysis. On the other hand, the standalone segment is estimated to likely to witness a decline in its share in the near future due to the increasing trend of incorporating all medical imaging devices with integrated software systems.

Hospitals, clinics, diagnostic centers, research and academic institutes, and ambulatory surgical centers (ASCs) have surfaced as the key end users of medical image analysis software, worldwide. The hospital segment, among these, emerged as the key contributor to this market in 2015 and is predicted to retain its lead throughout the forecast period. The presence of a well-established medical and healthcare industry and a favorable reimbursement scenario in developed regions, such as North America and Europe, have been driving the demand for medical image analysis software in hospitals and are expected to remain doing so over the next few years.

Rising Incidence of Cancer to Ensure Lead of North America

Geographically, Asia Pacific, Europe, Latin America, the Middle East and Africa, and North America have been considered as the main segments of the worldwide market for medical image analysis software. North America acquired the leading position in this market in 2015 with a share of 33.7% on the grounds of the rising incidence of cancer and cardiovascular diseases. Researchers anticipate the North America medical image analysis software market to maintain its dominance over the forthcoming years.

Europe, which was second in 2015, is projected to retain its position in the years to come. The economic developments, leading to the improvement in the healthcare facilities, are expected to prompt the key players to invest in this regional market for research and development activities, which may propel it substantially over the years to come. Asia Pacific, on the other hand, is predicted to be driven by the increasing prevalence of cancer, cardiovascular diseases, and other chronic disorders in countries, such as India and China and the rising awareness among consumers regarding early diagnosis of these diseases in the near future.

Get accurate market forecast and analysis on the Medical Image Analysis Software Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=5306

GE Healthcare, Siemens Healthineers, Agfa-Gevaert N.V., Hologic Inc., Pie Medical Imaging, Media Cybernetics Inc., AQUILAB, MIM Software Inc., Merge Healthcare Inc., and ScienceSoft USA Corp. are some of the key vendors of medical image analysis software across the world.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

Antidiabetics Market: Growth Analysis & Projections Forecast to 2023

The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for diabetes have become the focal point of attention due to the burgeoning diabetic population size, with diabetes affecting middle age groups and children across all income groups globally.

Browse through Antidiabetics Market report to know what factors will shape the market by 2023: http://www.transparencymarketresearch.com/antidiabetics-market.html

The anti-diabetics market has been segmented based on type of drug class into biguanides (metformin), sulfonylureas (glimepiride), meglitinides (repaglinide), thiazolidinediones (pioglitazone), dipeptidyl peptidase IV (DPP-IV) inhibitors (sitagliptin), and α-glucosidase inhibitors (acarbose).

Among these drug classes, Biguanides act directly against insulin resistance. Sulfonylureas (SUs) were the earliest drug classes in the market for treatment of diabetes and have a significant market presence. α-glucosidase inhibitors delay postprandial glucose absorption by hydrolysis of disaccharide is into monosaccharide’s in the small intestine.  Meglitinides are prandial insulin releasers that stimulate rapid insulin secretion. The thiazolidinediones are insulin-sensitizing drugs, which improve whole-body insulin sensitivity through gene regulation. DPP-IV inhibitors make a significant impact on glucose tolerance and make lasting improvements in the health outcomes of diabetic patients.

Some of the major drivers and opportunities for growth of this market include drug combinations of several agents such as sitagliptin and metformin and other drug combinations that are in different stages of clinical and pipeline development. Increase in the prevalence of diabetes and new product launches by major pharmaceutical companies re some of the key drivers for growth in this market. In 2015, Boehringer Ingelheim GmbH launched two new drugs (Synjardy & Glyxambi)for treatment of diabetes mellitus type II.

Some of the key opportunities for the antidiabetics include a strong pipeline for antidiabetics and entry of new players in the market, for instance, Novo Nordisk's diabetes drug’s Tresiba, and Ryzodeg received FDA approval in September 2015. Moreover, Boehringer Ingelheim GmbH has a strong pipeline for anti-diabetic drugs, such as Linagliptin which is a dipeptidyl peptidase (DPP) 4 inhibitor) for patients suffering from diabetes mellitus type II and high cardiovascular risk.

However, despite the availability of numerous branded antidiabetic drugs, many of these drugs have lost patent protection. In the wake of huge pressures from government and regulatory authorities, which have banned top selling drugs in various countries, in order to promote generic drugs at lower costs for diabetic patients. For instance, Mankind Pharma, launched anti-diabeticDynaglipt (Teneligliptin) under the drug class DPP-4 inhibitors in November 2015 in India targeting the middle to low income diabetic patient population.

As a result, the volume of antidiabetics is expected to shift to first generation drugs and other generic drugs in the market. Moreover, there is a huge unmet medical need for antidiabetics that can treat multiple chronic disorderscoexisting with diabetessuch as cardiovascular diseases, dyslipidemia, hypertension etc. Another major restraint in the antidiabetics market is reduction in the efficacy of drugs over a period and canlead to other health complications.

Get accurate market forecast and analysis on the Antidiabetics Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=8809

Some of the major players in the market include Astra Zeneca plc, Boehringer Ingelheim GmbH, Eli Lilly & Co., Johnson & Johnson, Mankind Pharma Ltd., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, SanofiS.A., and Teva Pharmaceutical Industries Ltd.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

Lymphoma Treatments Market: Research Report Forecast by 2023

Lymphoma is a kind of blood cancer which occurs when B or T lymphocytes and leukocytes grow abnormally. In addition, it also occurs if these cells survive longer than their normal life cycle. Lymphoma generally occurs in lymph nodes, bone marrow, spleen, blood and other organs which form a part of the lymphatic system. Lymphoma is of two types namely hodgkin and non-hodgkin. Hodgkin lymphoma develops in the lymph nodes of the lymphatic system. Non-Hodgkin lymphoma is the most common type of lymphoma and develops in related tissues of the lymphatic system and lymph nodes. The common symptoms of lymphoma are swelling of lymph nodes, fever, weight loss, night sweets, anorexia, itching, dyspnoea and fatigue. The common tests applied for the diagnosis of lymphoma are immunophenotyping, FISH (Fluorescence in Situ Hybridization) testing and flow cytometry. Radiation therapy, chemotherapy and monoclonal antibody therapy are performed on the patients suffering from lymphoma. Among all these treatment options, the most common method to treat lymphoma is chemotherapy.

Browse through Lymphoma Treatments Market report to know what factors will shape the market by 2023: http://www.transparencymarketresearch.com/lymphoma-treatment-drugs.html

Since chemotherapy destroys the cancer cell by obstructing its division process, it acts as one of the key method for lymphoma treatment. These medicines travel throughout the body while during the course of medication. Various drugs that are used for the treatment of lymphoma include Adcertis (brentuximab), Arranon (nelarabine), Adriamycin (doxorubicin), Decadron (dexamethasone), Baycadron (dexamethasone), Deltasone (prednisone), Dexamethasone Intensol (dexamethasone), Dexpak Taperpak (dexamethasone) and Folotyn (pralatrexate). Other drugs used include Prednicot (prednisone), Roferon-A (interferon alfa-2a), Solurex (dexamethasone), Leukeran (chlorambucil), Zema Pak (dexamethasone), Velcade (bortezomib), Sterapred DS (prednisone), Thioplex (thiotepa), Velban (vinblastine) and Trexall (methotrexate).

Rise in the incidence of lymphoma throughout the globe is expected to drive the growth of lymphoma treatments market. According to the Leukemia and Lymphoma Society, in 2012, around 700,000 people suffered from lymphoma in Canada alone. The government of various nations such as the U.S. and Europe has amplified their funding in R&D for the development of lymphoma treating drugs which would further augment the growth of lymphoma treatments market. Moreover, they have started many programs for patient awareness about lymphoma and its treatments. Despite all these advantages, various side effects of chemotherapy would hamper the growth of lymphoma treatments market. These side effects include hair loss, nausea, vomiting and fatigue. In addition, high cost of this treatment may also hamper the growth of lymphoma treatments market. Moreover, few nations such as the U.K are not providing reimbursement for every lymphoma treating drug which may also hamper its growth lymphoma treatments market.

Get accurate market forecast and analysis on the Lymphoma Treatments Market. Request a sample to stay abreast on the key trends impacting this market: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1396

In 2013, North America accounted for the largest share of global lymphoma treatments market. This is due to the fact that most of the key players who are engaged in developing and manufacturing lymphoma treating drugs are domiciled in the region. In addition, favorable government funding in the region has also contributed heavily in capturing the largest revenue share. During the forecast period 2014 to 2020, Asia-Pacific is expected to grow at the highest CAGR owing to rising incidences of lymphoma in the countries such as China, Malaysia and India. In addition, increasing disposable income coupled with rising healthcare expenditure would further accentuate the growth of lymphoma treatments market in the region. Major players operating in lymphoma treatments market include Abbott Laboratories, Eli Lilly and Company, Bristol-Myers Squibb Company, ABIOGEN PHARMA S.p.A., Johnson & Johnson, Aeterna Zentaris, Inc. and Merck & Co., Inc. among other significant players across the globe.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/